Nature Communications (Oct 2021)
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
- Priscilla K. Brastianos,
- Matthew R. Strickland,
- Eudocia Quant Lee,
- Nancy Wang,
- Justine V. Cohen,
- Ugonma Chukwueke,
- Deborah Anne Forst,
- April Eichler,
- Beth Overmoyer,
- Nancy U. Lin,
- Wendy Y. Chen,
- Aditya Bardia,
- Dejan Juric,
- Ibiayi Dagogo-Jack,
- Michael D. White,
- Jorg Dietrich,
- Naema Nayyar,
- Albert E. Kim,
- Christopher Alvarez-Breckenridge,
- Maura Mahar,
- Joana L. Mora,
- Brian V. Nahed,
- Pamela S. Jones,
- Helen A. Shih,
- Elizabeth R. Gerstner,
- Anita Giobbie-Hurder,
- Scott L. Carter,
- Kevin Oh,
- Daniel P. Cahill,
- Ryan J. Sullivan
Affiliations
- Priscilla K. Brastianos
- Massachusetts General Hospital
- Matthew R. Strickland
- Massachusetts General Hospital
- Eudocia Quant Lee
- Dana-Farber Cancer Institute
- Nancy Wang
- Massachusetts General Hospital
- Justine V. Cohen
- Massachusetts General Hospital
- Ugonma Chukwueke
- Dana-Farber Cancer Institute
- Deborah Anne Forst
- Massachusetts General Hospital
- April Eichler
- Massachusetts General Hospital
- Beth Overmoyer
- Dana-Farber Cancer Institute
- Nancy U. Lin
- Dana-Farber Cancer Institute
- Wendy Y. Chen
- Dana-Farber Cancer Institute
- Aditya Bardia
- Massachusetts General Hospital
- Dejan Juric
- Massachusetts General Hospital
- Ibiayi Dagogo-Jack
- Massachusetts General Hospital
- Michael D. White
- Massachusetts General Hospital
- Jorg Dietrich
- Massachusetts General Hospital
- Naema Nayyar
- Massachusetts General Hospital
- Albert E. Kim
- Massachusetts General Hospital
- Christopher Alvarez-Breckenridge
- Massachusetts General Hospital
- Maura Mahar
- Massachusetts General Hospital
- Joana L. Mora
- Massachusetts General Hospital
- Brian V. Nahed
- Massachusetts General Hospital
- Pamela S. Jones
- Massachusetts General Hospital
- Helen A. Shih
- Massachusetts General Hospital
- Elizabeth R. Gerstner
- Massachusetts General Hospital
- Anita Giobbie-Hurder
- Dana-Farber Cancer Institute
- Scott L. Carter
- Dana-Farber Cancer Institute
- Kevin Oh
- Massachusetts General Hospital
- Daniel P. Cahill
- Massachusetts General Hospital
- Ryan J. Sullivan
- Massachusetts General Hospital
- DOI
- https://doi.org/10.1038/s41467-021-25859-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 7
Abstract
Leptomeningeal metastases from solid tumors are a rare complication with a very poor prognosis. Here the authors report the efficacy and safety of combined ipilimumab and nivolumab in patients with leptomeningeal carcinomatosis.
